Showing results (31-40 of 6,985) with videos related to
Sort By:
Pageof 699
Cancer Science|January 23, 2016
ADAM23 is downregulated in side population and suppresses lung metastasis of lung carcinoma cellsMasahide Ota, Satsuki Mochizuki, Masayuki Shimoda, et al.Cancer Science|December 18, 2015
Utility of epirubicin-incorporating micelles tagged with anti-tissue factor antibody clone with no anticoagulant effectAkinori Sugaya, Ichinosuke Hyodo, Yoshikatsu Koga, et al.Cancer Science|December 18, 2015
Krüppel-like factor 4 promotes high-mobility group box 1-induced chemotherapy resistance in osteosarcoma cellsJun Huang, Ke Liu, Deye Song, et al.Cancer Science|December 19, 2015
Role of hemoglobin and transferrin in multi-wall carbon nanotube-induced mesothelial injury and carcinogenesisYue Wang, Yasumasa Okazaki, Lei Shi, et al.Cancer Science|January 23, 2016
Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trialMing Lu, Xicheng Wang, Lin Shen, et al.Cancer Science|March 31, 2016
Report of the Japan diabetes society/Japanese cancer association joint committee on diabetes and cancer, Second reportAtsushi Goto, Hiroshi Noto, Mitsuhiko Noda, et al.Cancer Science|March 23, 2016
Y-632 inhibits heat shock protein 90 (Hsp90) function by disrupting the interaction between Hsp90 and Hsp70/Hsp90 organizing protein, and exerts antitumor activity in vitro and in vivoWenqian Wang, Yang Liu, Zhixin Zhao, et al.Cancer Science|March 25, 2016
Cisplatin treatment increases stemness through upregulation of hypoxia-inducible factors by interleukin-6 in non-small cell lung cancerFuquan Zhang, Shanzhou Duan, Ying Tsai, et al.Cancer Science|March 26, 2016
Negative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapyKoji Tanaka, Hiroshi Miyata, Keijiro Sugimura, et al.Cancer Science|May 12, 2016
Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneityYusuke Ogitani, Katsunobu Hagihara, Masataka Oitate, et al.Pageof 699